Quantcast

Latest C-peptide Stories

2011-05-03 08:30:00

WORCESTER, Mass. and TORONTO, May 3, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced publication of results of studies applicable to the early diagnosis, and possibly treatment of, Type 1 diabetes. The study, entitled: "Recognition of Ii-Key/MHC Class II Epitope Hybrids Derived from Proinsulin and GAD Peptides by T Cells in Type 1 Diabetes" appears in the April issue of the international peer-reviewed journal Hormone and Metabolism...

2011-04-04 08:00:00

LELYSTAD, The Netherlands, April 4, 2011 /PRNewswire/ -- Pepscan Therapeutics, the Dutch biotech company focusing on protein mimicry for the discovery of therapeutics peptides and antibodies, announced today the appointment of Michiel Lodder as Chief Business Officer. Dr. Lodder joins Pepscan from Octoplus, where he held the position of Senior Manager Business Development, responsible for licensing, partnering, and alliance management activities. "We are delighted to bring Michiel...

2011-03-30 06:00:00

SAN MATEO, Calif., March 30, 2011 /PRNewswire/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced the schedule of its upcoming cenderitide presentation taking place at the American College of Cardiology (ACC) 60th Scientific Session, April 2-5th. Location: Ernest N. Morial Convention Center, Hall FDate: Sunday, April 3, 2011Time: 10:00 AM -11:15 AM (CDT)Poster Presentation: Board #256...

2011-02-28 06:00:00

SAN MATEO, Calif., Feb. 28, 2011 /PRNewswire/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a biopharmaceutical company focused on the development of novel therapeutics for cardiovascular disease, announced plans to pursue a new indication in the field of heart failure. Nile plans to develop cenderitide (formerly CD-NP) as an outpatient therapy to be delivered to acutely decompensated heart failure (ADHF) patients continuously for up to 90 days after discharge from the hospital. This is a...

2011-02-22 06:30:00

QUÓ°BEC CITY, Feb. 22 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that its Vice President, Alliance Management and Intellectual Property, Eckhard Guenther, Ph.D., will make a presentation on two of the Company's novel anticancer compounds, AEZS-108 and AEZS-129, at Bio Partnering North America on Monday, February 28, 2011, at 4 p.m. (Pacific Time) in the West Meeting Room 218, of the Vancouver Convention...

2011-02-18 07:26:00

CRANBURY, N.J., Feb. 18, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) will host a conference call and webcast on February 24, 2011 at 11:00 a.m. Eastern Time to discuss its quarter ended December 31, 2010 financial results and plans for its programs under development. Schedule for the Financial Results Press Release, Conference Call / Webcast -- Q2 Fiscal Year 2011 Conference Call-Live 2/24/2011 at 11:00 a.m. ET Domestic Dial-In Number...

2011-01-18 06:30:00

NES-ZIONA, Israel, Jan. 18, 2011 /PRNewswire/ -- PROLOR Biotech, Inc., (NYSE Amex: PBTH), today announced that it has entered into a definitive license agreement with Yeda Research and Development Company Ltd. for novel technology utilized in the development of long-acting therapeutic peptides and small molecules, termed Reversible PEGylation. The Reversible PEGylation technology has been shown in animal models to significantly enhance the half-life and improve the biological activity of a...

2011-01-03 09:00:00

WALTHAM, Massachusetts and LELYSTAD, The Netherlands, January 3, 2011 /PRNewswire/ -- Mercator Therapeutics, the first biopharmaceutical company to systematically use in vivo phage display technology to develop novel cancer drugs and Pepscan Therapeutics, a world leader in protein mimicry technologies for improved therapeutic peptides and anti-GPCR antibodies, today announced a multi-program research collaboration. The companies will collaborate to optimize Mercator's 'Homing Peptides'...

2010-11-15 08:20:00

JERUSALEM, November 15, 2010 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals Inc. (OTCBB: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, presented the results of its recently completed Phase IIb trial. The multicenter, placebo-controlled, randomized, double-blind study conducted in 29 patients with Type II diabetes assessed the safety of ORMD-0801 in patients with Type II diabetes. Results were presented by the company's Chief Scientific Officer, Dr. Miriam...

2010-11-02 06:30:00

CRANBURY, N.J., Nov. 2, 2010 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN), announced today that it has received $978,000 in grants under the Patient Protection and Affordable Care Act of 2010 (PPACA), with $847,000 available immediately and $131,000 available no later than 30 days after Palatin's fiscal year ending June 30, 2011. The grants are related to four of Palatin's projects - melanocortin agonists for sexual dysfunction; melanocortin agonists for obesity and...


Word of the Day
tesla
  • The unit of magnetic flux density in the International System of Units, equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.
This word is named for Nikola Tesla, the inventor, engineer, and futurist.